2021 Revenues ($USD) : $258,973,000
2021 R&D spend : $41,061,000
2021 Number of Employees : 780
Fiscal Year End : 6/30/2021
Key People : Scott Ward, chair, president and CEO; Robert Beverly, VP and GM, peripheral sales; Harrison Boyd, VP and GM, coronary sales; Ryan Egeland, chief medical officer; John Hastings, VP, manufacturing and operations; Jack Nielsen, VP, investor relations and corporate communications; Jeffrey Points, CFO; Stephen Rempe, chief human resources officer; Rhonda Robb, chief operating officer; Alexander Rosenstein, general counsel and corporate secretary; Sandra Sedo, chief compliance officer; Christopher Volker, VP and GM, international; David Whitescarver, VP, corporate development and intellectual property.

About the company: Cardiovascular Systems is developing treatment devices for peripheral and coronary artery disease. The St. Paul, Minnesota-based company has six devices in its peripheral portfolio, including the Diamondback 360 peripheral orbital atherectomy system exchangeable series, Diamondback 360 peripheral orbital atherectomy system, Zilient peripheral guidewires, Teleport microcatheter, ViperCath XC peripheral exchange catheter, Wirion peripheral embolic protection system, Jade PTA balloon catheter and the Sapphire II Pro dilation catheter. Cardiovascular Systems has three coronary artery devices: Diamondback 360 coronary orbital atherectomy system, Teleport microcatheter and Sapphire balloons.  –DK